Dr Reddys Laboratories Ltd management interview: Dr. Reddy’s Q2: Profit Falls 36%, But Margins Beat Street Estimates | Business News | ET Now
ET Now, 2026-10-23. Video: https://www.youtube.com/watch?v=jCWJhLqCY7k
- Earnings drivers: EBITDA margin was 20.6%, above Street estimates of 14.9%, though lower year-on-year after the company lost last year’s lenalidomide sales. Management said sales grew without costs rising, supported by US launches including bortezomib and sugammadex, and growth in India and emerging markets.
- North America outlook: Revenue fell 23% year-on-year due to lower lenalidomide sales, but excluding lenalidomide the business grew double digit; management expects double-digit North America growth this year. It said FDA observations are addressable, responses were submitted on time, and it sees no current sales concern.
- Launch pipeline: Dr. Reddy’s continues selling semaglutide in India, plans to relaunch it in Canada in November and launch in 10 more markets from November until March. Abatacept is ready and awaiting FDA action, with a goal date in December; the company has about 20 new US products and has launched quite a few.
- India and CDMO: India revenue grew 17% year-on-year, driven mainly by innovative products licensed from originators; management expects nivolumab to do well and said abatacept is primarily for the US and Europe. The CDMO business is growing across discovery and CMO, with potential to reach 2 or 3 times its current level.
- Investment and PSAI: Management plans to invest 7% to 8% of sales in R&D and expects annual capex of ₹1,500 to ₹3,000 crore, alongside licensing products. PSAI revenue declined 12% year-on-year, but management called it profitable and strategic; margin pressure reflects changing demand for some products.